Medtech Investing for Wholesale Investors

Medtech sits alongside biotech in healthcare but with a different risk profile. Medical devices, diagnostics and digital health often follow shorter regulatory paths than new drugs and can reach commercial revenue earlier, frequently with recurring income from consumables, software or service contracts. It is a way to back healthcare innovation with somewhat more predictable commercial outcomes than pure therapeutics.

For Boston Global Wealth clients, medtech is accessed mainly through diversified growth and late-stage private funds that hold it as a theme, plus selective co-investments where the Boston Global Group network has sourcing relationships. It remains a growth allocation with real risk, sized within a broader portfolio. This page is general advice only.

What it is

Investment in companies developing medical devices, diagnostics, surgical robotics, imaging, in-vitro testing and digital-health platforms. The opportunity set runs from venture-stage developers to commercial businesses with recurring revenue from consumables, software or services.

Why investors consider it

Device and diagnostic approval pathways are typically faster than new-drug approvals, and successful products can generate annuity-style revenue through consumables and service contracts. Demand is supported structurally by rising healthcare spending and ageing populations.

How the exposure is built

Through diversified late-stage and growth-stage private funds on the approved list that include medtech as a theme, selective direct co-investments where BGW has sourcing relationships, and listed exposure where liquidity is preferred.

How BGW manages the risk

Risk is spread across companies, stages and sub-themes rather than concentrated in a single device or business, and positions are sized to the client's overall portfolio.

Where it fits

A growth allocation for investors seeking healthcare exposure with somewhat earlier commercial outcomes than biotech, still sized as part of a diversified portfolio.

Risks to weigh

Medtech is generally lower-variance than biotech, but it is not low-risk. The main risks to weigh:

Reimbursement risk. Whether and how a device is funded by health systems or insurers can make or break its commercial case.
Regulatory risk. Approvals can still be delayed, and requirements can change.
Competition and obsolescence. Technology moves quickly; a better device can displace an incumbent.
Liquidity or volatility. Private positions are illiquid until an exit; listed positions carry single-stock volatility.
Adoption risk. Clinicians and hospitals can be slow to change established practice.
Concentration risk. Outcomes for a single company or product can dominate a position.

Frequently asked questions

What is medtech investing?

Medtech investing means backing companies that make medical devices, diagnostics and digital-health tools. Investors aim to benefit from products that reach market and generate recurring revenue.

How is medtech different from biotech?

Biotech develops drugs and therapies with often binary clinical outcomes; medtech develops devices and diagnostics that usually have shorter regulatory paths and can reach revenue earlier, which tends to make outcomes somewhat more predictable.

How can Australian wholesale investors access medtech?

Mainly through diversified growth and late-stage private funds that include medtech, and selective co-investments, with some listed exposure where liquidity is preferred.

What are the risks of medtech?

Reimbursement and regulatory uncertainty, competition and obsolescence, illiquidity or volatility, and single-company risk. Returns are not guaranteed and capital is at risk.

Who can invest in these medtech strategies?

They are generally available to wholesale or sophisticated investors as defined under section 708 of the Corporations Act.

General advice only. This information does not consider your objectives, financial situation or needs; consider the relevant disclosure document and seek personal advice before investing. Any target returns are indicative only and not guaranteed. Past performance is not a reliable indicator of future performance. Private market investments carry liquidity, valuation and concentration risks and are generally restricted to wholesale or sophisticated investors under section 708 of the Corporations Act.